Psyence Biomedical (PBM) News Today $0.07 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Psyence Biomedical Acquires Stake in PsyLabsNovember 2 at 6:17 AM | markets.businessinsider.comPsyence Group closes disposal of stake in PsyLabsOctober 31, 2024 | markets.businessinsider.comPsyence Biomedical closes acquisition of Psyence Group’s stake in PsyLabsOctober 31, 2024 | markets.businessinsider.comPsyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabsOctober 31, 2024 | globenewswire.comPsyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabsOctober 31, 2024 | markets.businessinsider.comShort Interest in Psyence Biomedical Ltd. (NASDAQ:PBM) Increases By 181.5%October 28, 2024 | americanbankingnews.comPsyence recruits Empax Center as second trial site for Phase IIb trialOctober 25, 2024 | markets.businessinsider.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CareOctober 25, 2024 | globenewswire.comPsyence Biomedical Plans Key Shareholder MeetingOctober 24, 2024 | markets.businessinsider.comPsyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CareOctober 24, 2024 | globenewswire.comPsyence Group Inc. (PSYGF)October 18, 2024 | finance.yahoo.comPsyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) DevelopmentOctober 17, 2024 | globenewswire.comPsyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence BiomedicalOctober 14, 2024 | globenewswire.comPsyence Biomedical (NASDAQ:PBM) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comPsyence Biomedical (NASDAQ:PBM) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPsyence Biomed Provides Update on Previously Announced Acquisition of ClairvoyantOctober 4, 2024 | globenewswire.comPsyence Group Inc.: Psyence Group Enters into Agreement to Dispose of Stake in PsyLabsSeptember 20, 2024 | finanznachrichten.dePsyence Group Enters into Agreement to Dispose of Stake in PsyLabsSeptember 20, 2024 | globenewswire.comPsyence Biomed Enters into Agreement to Acquire Stake in PsyLabsSeptember 19, 2024 | globenewswire.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesSeptember 18, 2024 | globenewswire.comPsyence Biomedical Ltd.: Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesSeptember 16, 2024 | finanznachrichten.dePsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative CareSeptember 16, 2024 | globenewswire.comPsyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesSeptember 16, 2024 | globenewswire.comPsyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from NasdaqSeptember 13, 2024 | globenewswire.comPsyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative CareSeptember 9, 2024 | msn.comPsyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative CareSeptember 9, 2024 | globenewswire.comPsyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer ClairvoyantSeptember 6, 2024 | globenewswire.comPsyence Biomedical (PBM) Stock Is Down 30%: What's Going On?September 4, 2024 | benzinga.comPsyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SECAugust 30, 2024 | globenewswire.comPsyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024August 27, 2024 | globenewswire.comPsyence Biomedical files for potential secondary stock offeringAugust 19, 2024 | msn.comOptimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug DevelopmentAugust 13, 2024 | globenewswire.comPsyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLCJuly 31, 2024 | globenewswire.comPsyence Biomedical Ltd. (PBM)July 31, 2024 | finance.yahoo.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialJuly 26, 2024 | globenewswire.comPsyence Biomedical Ltd.: Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialJuly 26, 2024 | finanznachrichten.deWhy Psyence Biomedical (PBM) Stock Is SkyrocketingJuly 26, 2024 | msn.comWhy Is Psyence Biomedical (PBM) Stock Up 163% Today?July 25, 2024 | investorplace.comPsyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialJuly 24, 2024 | globenewswire.comPsyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJuly 3, 2024 | globenewswire.comPsyence Biomed to Participate in the A.G.P. Virtual Healthcare Company ShowcaseMay 17, 2024 | globenewswire.comPsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)April 17, 2024 | finance.yahoo.comPsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)April 17, 2024 | globenewswire.comPsyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialApril 16, 2024 | globenewswire.comPsyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin TrialApril 8, 2024 | tmcnet.comPsyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialApril 8, 2024 | globenewswire.comPsyence Group Inc.: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessMarch 28, 2024 | finanznachrichten.dePsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessMarch 26, 2024 | globenewswire.comPsyence Biomedical Ltd PBMMarch 24, 2024 | morningstar.comPBM Psyence Biomedical Ltd.March 22, 2024 | seekingalpha.com Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER… PBM Media Mentions By Week PBM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBM News Sentiment▼0.160.46▲Average Medical News Sentiment PBM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBM Articles This Week▼51▲PBM Articles Average Week Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Organovo News Hoth Therapeutics News Eterna Therapeutics News Alterity Therapeutics News Vaccinex News Cardio Diagnostics News Biomerica News GeoVax Labs News NuCana News Adial Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBM) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBM Stock Alerts